Article citationsMore>>

Roy, D., Pratt, C.M., Torp-Pedersen, C., Wyse, D.G., Toft, E., Juul-Moller, S., et al., for the Atrial Arrhythmia Conversion Trial Investigators (2008) Vernakalant hydro- chloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial. Circulation, 117, 1518-1525. doi:10.1161/CIRCULATIONAHA.107.723866

has been cited by the following article:

• TITLE: Novel therapies for treating atrial fibrillation

  AUTHORS: Raj Parikh, Philip J. Kadowitz

  KEYWORDS: Atrial Fibrillation; Atrial Flutter; Arrhythmia;Anticoagulation; Stroke

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.2 No.4, October 30, 2012

  ABSTRACT: Atrial fibrillation is the most common cardiac arrhythmia and is a major risk factor for stroke, heart failure, and death. Current treatments focus on anti-coagulation as well as rate-control and rhythm-control strategies. Frequent INR checks associated with warfarin along with several adverse side effects of anti-arrhythmics have propelled investigations into novel treatments for atrial fibrillation. Research is focused not only on pioneering new pharmacological antico- agulation and anti-arrhythmic agents but also on improving surgical techniques in hopes of treating the arrhythmia. Here, we first briefly discuss the current treatment options, both pharmacological and non-pharmacological, for atrial fibrillation. We then present a focused review of recent animal and human investigations that examine the use of novel an-ticoagulation agents, mechanisms of new anti-arrhythmics, analyze potential triggers of atrial fibrillation, and highlight the role of genetics in atrial fibrillation.